查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750848

再生醫學市場規模、佔有率、趨勢分析報告：按產品、治療類別、地區、細分市場預測，2025-2030 年

Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Therapeutics, Tools, Banks), By Therapeutic Category (Dermatology, Musculoskeletal, Immunology & Inflammation), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 245 Pages | 商品交期: 2-10個工作天內

價格

再生醫學市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球再生醫學市場規模預計在2025年至2030年期間以16.83%的複合年成長率成長，到2030年將達到900.1億美元。

強大的產品線是再生醫學市場的主要驅動力之一，因為公司正在大力投資研發，以最新技術升級其產品並滿足客戶未滿足的需求。

此外，隨著疾病治療需求的不斷成長，各公司正致力於加速針對基因組層面疾病病因的基因療法的研發。根據美國藥物研究與製造商協會（PhRMA）發布的數據，美國在研項目（I-III期臨床試驗）中的細胞和基因治療藥物數量從2018年的289種增加到2019年的362種，一年內增加了25%。該領域的持續進步可能會進一步刺激再生醫學的需求。

幹細胞、組織工程、奈米技術和其他技術的進步使再生醫學成為一個高度跨學科的領域。幹細胞是未分化的細胞，具有修復和再生其他細胞（例如軟骨、肌腱、韌帶、肌肉和骨骼）的能力。 2021年7月，BlueRock Therapeutics公司獲得FDA核准，其多功能細胞衍生的多巴胺能神經元療法DA01用於治療進行性帕金森氏症。此次核准預計將擴大該公司的產品陣容。

一些關鍵參與者正在採取新產品開發和策略聯盟等策略性舉措，促進再生醫學市場的成長。例如，2021年11月，Astellas來製藥與Pantherna Therapeutics GmbH簽署協議，共同研究基於mRNA的再生醫學。根據該協議，Astellas來製藥強大的藥物研發能力和Pantherna先進的mRNA平台將用於推進新專案的研究和開發。此外，2021年5月，拜耳股份公司與Senti Bio簽署了一項合作研究協議，旨在開發結合基因迴路的再生醫學細胞療法。

再生醫學市場報告重點

  • 由於老齡化社會的進展和與老齡化的疾病的增加，治療藥物部分佔據再生醫學市場的最大佔有率。
  • 預計針對幹細胞和組織再生療法的臨床試驗的增加以及對再生療法的需求的不斷成長將對市場成長產生積極影響。
  • 由於研發方面的巨大投入和幹細胞庫的增加，基於幹細胞和前驅細胞的治療方法預計將經歷顯著成長。
  • 由於北美地區有大量從事幹細胞治療方法研究和開發的研究機構和大學，預計到 2024 年北美將佔據市場主導地位。
  • 由於醫療保健行業迅速採用基於細胞的方法，預計亞太地區將在未來幾年見證最快的成長。
  • 從治療領域來看，腫瘤治療將在2024年佔據市場主導地位，因為全球癌症患者數量的成長推動了對更優解決方案的需求。強勁且不斷成長的產品線正在推動市場成長。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場趨勢與展望
    • 市場動態
    • 市場限制因素分析
  • 商業環境分析
    • PESTEL分析
    • 波特五力分析
    • COVID-19影響分析

第4章 產品業務分析

  • 細分儀表板
  • 全球再生醫學市場：產品趨勢分析
  • 治療
    • 初代細胞治療
    • 基於幹細胞和前驅細胞的治療方法
    • 細胞免疫療法
    • 基因治療
  • 工具
  • 銀行
  • 服務

5. 治療類別業務分析

  • 細分儀表板
  • 全球再生醫學市場：治療類別變化分析
  • 皮膚科
  • 肌肉骨骼
  • 免疫學和炎症
  • 腫瘤學
  • 心血管系統
  • 眼科
  • 其他

第6章區域業務分析

  • 2024 年及 2030 年全球再生醫學市場佔有率
  • 北美洲
    • 2018-2030年北美再生醫學市場
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030年歐洲再生醫學市場
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030年亞太再生醫學市場
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 2018-2030年拉丁美洲再生醫學市場
    • 巴西
    • 阿根廷
  • 中東和非洲
    • MEA 再生醫學市場，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 公司分類
  • 戰略地圖
  • 2024年企業市場分析
  • 公司簡介/列表
    • AstraZeneca plc.
    • F. Hoffmann-La Roche Ltd.
    • Integra Lifesciences Corp.
    • Astellas Pharma, Inc.
    • Cook Biotech, Inc.
    • Bayer AG
    • Pfizer, Inc.
    • Merck KGaA
    • Abbott
    • Vericel Corp.
    • Novartis AG
    • GlaxoSmithKline
Product Code: GVR-1-68038-952-4

Regenerative Medicine Market Growth & Trends:

The global regenerative medicine market size is expected to reach USD 90.01 billion by 2030, expanding at a CAGR of 16.83% from 2025 to 2030, according to a new report by Grand View Research, Inc. The presence of a strong pipeline is one of the major drivers in the regenerative medicine market. Companies invest heavily in R&D to upgrade their products with the latest technology and fulfil the unmet needs of their customers.

Furthermore, with the increasing demand for disease treatment therapies, companies have focused their efforts to accelerate R&D for gene therapies that target the cause of disease at a genomic level. The cell and gene therapies in the U.S. pipeline programs (Phase I-III trials) grew from 289 in 2018 to 362 by 2019 according to the data published by PhRMA,. This represents an increase of 25% in a single year. Continuous advancements in this field would further boost the demand for regenerative medicines.

Technological advancements such as stem cells, tissue engineering, and nanotechnology has made regenerative medicines a highly interdisciplinary in field. Stem cells are undifferentiated cells, which have the capability to repair and/or regenerate into other cells such as cartilage, tendons, ligaments, muscle, and bones. In July 2021, BlueRock Therapeutics received FDA approval for its pluripotent stem cell-derived dopaminergic neuron therapy, DA01, for advanced Parkinson's disease treatment. This approval was expected to expand the company's offerings.

Several key players are taking strategic initiatives such as new product development, strategic alliances, and others have contributed to the regenerative medicine market growth. For instance, in November 2021, Astellas Pharma, Inc. entered into an agreement with Pantherna Therapeutics GmbH to study mRNA-based regenerative medicine. Under this initiative, Astellas' high drug discovery capabilities and Pantherna's state-of-the-art mRNA platform will be used to promote research on developing a new program. In addition, in May 2021, Bayer AG entered into a collaboration with Senti Bio for gene circuit-engineered cell therapies development for regenerative medicine.

Regenerative Medicine Market Report Highlights:

  • The therapeutics segment held the largest share in the regenerative medicine market, owing to the growing aging population coupled with an increasing rate of age-related disorders.
  • The rise in a number of clinical trials for stem cell and tissue-based regenerative therapies along with an increase in demand for regenerative therapies is expected to positively influence the growth of the market.
  • Stem cell and progenitor cell-based therapies are projected to witness significant growth owing to huge investments in the R&D space and a growing number of stem cell banks
  • North America dominated the market in 2024 owing to the presence of a significant number of research organizations and universities which are working on R&D of stem cell-based therapies.
  • Asia Pacific is anticipated to witness the fastest growth in the coming years owing to the rapid adoption of cell-based methods in the healthcare industry.
  • By therapeutic category, the oncology segment dominated the segment in 2024 owing to the increasing cases of cancer globally which is rising the demand for better solutions. The growing number of robust pipelines is driving the market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Therapeutic Category
  • 1.3. Research Methodology
  • 1.4. Information Procurement
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
    • 3.2.1. Market Dynamics
      • 3.2.1.1. Presence of a strong pipeline and a large number of clinical trials
      • 3.2.1.2. High economic impact of regenerative medicine
      • 3.2.1.3. Emerging applications of gene therapy in regenerative medicine
      • 3.2.1.4. Increasing government & private funding to support the development of regenerative medicine
      • 3.2.1.5. Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
      • 3.2.1.6. Increase in strategic partnerships to accelerate the development & commercialization of regenerative medicines
      • 3.2.1.7. Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to a rise in demand for regenerative treatments
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Regulatory issues pertaining to stem cells, tissue engineering, and regenerative medicines
  • 3.3. Business Environment Analysis
    • 3.3.1. PESTEL Analysis
    • 3.3.2. Porter's Five Forces Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Regenerative Medicine Market: Product Movement Analysis
  • 4.3. Therapeutics
    • 4.3.1. Therapeutics Market, 2018 - 2030 (USD Million)
    • 4.3.2. Primary Cell-Based Therapeutics
      • 4.3.2.1. Primary Cell-Based Therapeutics Market, 2018 - 2030 (USD Million)
      • 4.3.2.2. Dermatology
        • 4.3.2.2.1. Dermatology Market, 2018 - 2030 (USD Million)
      • 4.3.2.3. Musculoskeletal
        • 4.3.2.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
      • 4.3.2.4. Surgical
        • 4.3.2.4.1. Surgical Market, 2018 - 2030 (USD Million)
      • 4.3.2.5. Dental
        • 4.3.2.5.1. Dental Market, 2018 - 2030 (USD Million)
      • 4.3.2.6. Others
        • 4.3.2.6.1. Others Market, 2018 - 2030 (USD Million)
    • 4.3.3. Stem Cell & Progenitor Cell-based therapeutics
      • 4.3.3.1. Stem Cell & Progenitor Cell-based therapeutics Market, 2018 - 2030 (USD Million)
      • 4.3.3.2. Autologous
        • 4.3.3.2.1. Autologous Market, 2018 - 2030 (USD Million)
      • 4.3.3.3. Allogenic
        • 4.3.3.3.1. Allogenic Market, 2018 - 2030 (USD Million)
      • 4.3.3.4. Others
        • 4.3.3.4.1. Others Market, 2018 - 2030 (USD Million)
    • 4.3.4. Cell-based Immunotherapies
      • 4.3.4.1. Cell-based Immunotherapies Market, 2018 - 2030 (USD Million)
    • 4.3.5. Gene Therapies
      • 4.3.5.1. Gene Therapies Market, 2018 - 2030 (USD Million)
  • 4.4. Tools
    • 4.4.1. Tools Market, 2018 - 2030 (USD Million)
  • 4.5. Banks
    • 4.5.1. Banks Market, 2018 - 2030 (USD Million)
  • 4.6. Services
    • 4.6.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Therapeutic Category Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Regenerative Medicine Market: Therapeutic Category Movement Analysis
  • 5.3. Dermatology
    • 5.3.1. Dermatology Market, 2018 - 2030 (USD Million)
  • 5.4. Musculoskeletal
    • 5.4.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
  • 5.5. Immunology & Inflammation
    • 5.5.1. Immunology & Inflammation Market, 2018 - 2030 (USD Million)
  • 5.6. Oncology
    • 5.6.1. Oncology Market, 2018 - 2030 (USD Million)
  • 5.7. Cardiovascular
    • 5.7.1. Cardiovascular Market, 2018 - 2030 (USD Million)
  • 5.8. Ophthalmology
    • 5.8.1. Ophthalmology Market, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Global Regenerative Medicine Market Share By Region, 2024 & 2030
  • 6.2. North America
    • 6.2.1. North America Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Competitive Scenario
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. U.S. Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Competitive Scenario
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Canada Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Competitive Scenario
      • 6.2.4.3. Regulatory Framework
      • 6.2.4.4. Mexico Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Germany Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. UK Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. France Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Competitive Scenario
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Italy Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Competitive Scenario
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Spain Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Competitive Scenario
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Denmark Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Competitive Scenario
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Sweden Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Competitive Scenario
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Norway Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Japan Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. China Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. India Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. South Korea Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Australia Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Thailand Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Brazil Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Argentina Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. MEA Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. South Africa Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Saudi Arabia Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. UAE Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Kuwait Regenerative Medicine Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2024
  • 7.4. Company Profiles/Listing
    • 7.4.1. AstraZeneca plc.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. F. Hoffmann-La Roche Ltd.
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Integra Lifesciences Corp.
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Astellas Pharma, Inc.
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Cook Biotech, Inc.
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Bayer AG
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Pfizer, Inc.
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Merck KGaA
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Abbott
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Vericel Corp.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. Novartis AG
      • 7.4.11.1. Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. GlaxoSmithKline
      • 7.4.12.1. Overview
      • 7.4.12.2. Financial Performance
      • 7.4.12.3. Product Benchmarking
      • 7.4.12.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 4 Global Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 5 North America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 6 North America Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 7 North America Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 8 U.S Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 9 U.S Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 10 Canada Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 11 Canada Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 12 Mexico Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 13 Mexico Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 14 Europe Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 16 Europe Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 17 Germany Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 18 Germany Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 19 U.K Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 20 U.K Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 21 France Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 22 France Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 23 Italy Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 24 Italy Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 25 Spain Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 26 Spain Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 27 Denmark Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 28 Denmark Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 29 Norway Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 30 Norway Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 31 Sweden Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 32 Sweden Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 36 China Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 37 China Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 38 Japan Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 39 Japan Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 40 India Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 41 India Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 42 Australia Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 43 Australia Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 44 South Korea Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 45 South Korea Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
  • Table 46 Thailand Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 47 Thailand Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
  • Table 48 Latin America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 49 Latin America Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 50 Latin America Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 51 Brazil Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 52 Brazil Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 53 Argentina Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 54 Argentina Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 58 South Africa Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 59 South Africa Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 62 UAE Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 63 UAE Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 64 Kuwait Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 66 Participant's Overview
  • Table 67 Financial Performance
  • Table 68 Key Companies Undergoing Expansions
  • Table 69 Key Companies Undergoing Acquisitions
  • Table 70 Key Companies Undergoing Collaborations
  • Table 71 Key Companies Launching New Products/Services
  • Table 72 Key Companies Undergoing Partnerships
  • Table 73 Key Companies Undertaking Other Strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary Others pattern
  • Fig. 4 Market Others approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market summary, 2024 (USD Million)
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Market driver impact
  • Fig. 11 Market restraint impact
  • Fig. 12 Porter's analysis
  • Fig. 13 SWOT analysis
  • Fig. 14 Global regenerative medicine therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 15 Global primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 16 Global dermatology primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 17 Global musculoskeletal primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 18 Global surgical primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 19 Global dental primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 20 Global other primary cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 21 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 22 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 23 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 24 Global other stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 25 Global cell-based immunotherapies market, 2018 - 2030 (USD Million)
  • Fig. 26 Global gene therapies market, 2018 - 2030 (USD Million)
  • Fig. 27 Global regenerative medicines tools, 2018 - 2030 (USD Million)
  • Fig. 28 Global banks market for regenerative medicine, 2018 - 2030 (USD Million)
  • Fig. 29 Global regenerative medicine services market, 2018 - 2030 (USD Million)
  • Fig. 30 Regenerative medicine market: Therapeutic category outlook and key takeaways
  • Fig. 31 Regenerative medicine market: Therapeutic category movement analysis (USD Million)
  • Fig. 32 Global dermatological therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 33 Global musculoskeletal therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 34 Global immunology & inflammation therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 35 Global oncology therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 36 Global cardiovascular therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 37 Global ophthalmology therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 38 Global other therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 39 Global Regenerative Medicine Market: Regional outlook and key takeaways
  • Fig. 40 North America Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 41 U.S key country dynamics
  • Fig. 42 U.S Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 43 Canada key country dynamics
  • Fig. 44 Canada Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico key country dynamics
  • Fig. 46 Mexico Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Europe Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Germany key country dynamics
  • Fig. 49 Germany Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 France key country dynamics
  • Fig. 51 France Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 U.K key country dynamics
  • Fig. 53 U.K Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Italy key country dynamics
  • Fig. 55 Italy Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Spain key country dynamics
  • Fig. 57 Spain Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark key country dynamics
  • Fig. 59 Denmark Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Sweden key country dynamics
  • Fig. 61 Sweden Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Norway key country dynamics
  • Fig. 63 Norway Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Asia-Pacific Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 China key country dynamics
  • Fig. 66 China Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 India key country dynamics
  • Fig. 68 India Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea key country dynamics
  • Fig. 70 South Korea Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 Japan key country dynamics
  • Fig. 72 Japan Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Australia key country dynamics
  • Fig. 74 Australia Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Thailand key country dynamics
  • Fig. 76 Thailand Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 Latin America Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Brazil key country dynamics
  • Fig. 79 Brazil Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Argentina key country dynamics
  • Fig. 81 Argentina Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 MEA Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 South Africa key country dynamics
  • Fig. 84 South Africa Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Saudi Arabia key country dynamics
  • Fig. 86 Saudi Arabia Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 87 UAE key country dynamics
  • Fig. 88 UAE Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 89 Kuwait key country dynamics
  • Fig. 90 Kuwait Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 91 Market participant categorization
  • Fig. 92 Strategy framework